Alto Neuroscience (ANRO) news
Recent news
Alto Neuroscience - Promotes Nick Smith to president and CFO effective August 26, 2026
AInvest Wire · 3d agoAlto Neuroscience - proceeds to accelerate clinical development of Alto-207 and for working capital
Alto Neuroscience Inc. (NASDAQ: ALTO) has announced a $45 million equity financing round to support the accelerated clinical development of its lead candidate, Alto-207, and to strengthen its working capital position [1]. The financing includes participation from existing institutional investors…
AInvest Wire · Jul 13, 2026Alto Neuroscience prices $100M registered direct offer stock
Alto Neuroscience Inc. has announced the pricing of a $100 million registered direct offering of its common stock, with the transaction expected to close in the coming weeks. The offering includes the sale of 10 million shares at a price of $10 per share, with net proceeds to be used for general…
AInvest Wire · Jul 13, 2026Alto Neuroscience - to accelerate and expand clinical development of Alto-207 with additional planned Phase 3 trial - SEC filing
Alto Neuroscience, Inc. (NYSE: ANRO) has announced plans to accelerate and expand the clinical development of ALTO-207, a fixed-dose combination therapy for treatment-resistant depression (TRD), with the initiation of a Phase 2b trial and preparations for a potential Phase 3 study. The company…
AInvest Wire · Jul 13, 2026Alto Neuroscience fell 58.7% after it announced treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker.
Alto Neuroscience fell 58.7% after it announced treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker. Introduction: Alto Neuroscience Inc. (ALTO), a clinical-stage biopharmaceutical company…
AInvest Wire · Oct 23, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.